Multiple Myeloma

Meta-analysis of whole-body MRI versus FDG PET/CT to assess treatment response in MM may suggest a complementary benefit when utilizing both modalities.

Updated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM.

Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics.

REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/refractory multiple myeloma.

Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.

In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.

Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits.

Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy.

Phase 1 data of ALLO-715 followed by lymphodepletion showed durable responses in heavily pretreated RRMM patients.

Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.